Scientific article

Thérapies ciblées du cancer pulmonaire: tests moléculaires à partir d'échantillons cytologiques

Published inRevue médicale suisse, vol. 7, no. 303, p. 1486-1490
Publication date2011

Important advances in lung cancer treatment have been made over the last decade. Several drugs designed to target molecular pathways involved in cancer-cell growth and survival have been shown to be effective in a selected fraction (<20%) of non-small cell lung cancer patients. Somatic mutations in several genes (i.e.: EGFR and KRAS) can predict patient's response to targeted therapies. Those mutations are commonly detected on histopathological samples (core-needle biopsy/ surgical resection). However, when tissue biopsies are not available, molecular testing has to be performed on cytological specimens. Issues raised by molecular testing on cytological specimen are discussed in this article.

  • Carcinoma, Non-Small-Cell Lung/genetics/pathology
  • Humans
  • Lung Neoplasms/genetics/pathology
  • Mutation
  • Proto-Oncogene Proteins/genetics
  • Receptor, Epidermal Growth Factor/genetics
  • Ras Proteins/genetics
Citation (ISO format)
PUSZTASZERI, Marc et al. Thérapies ciblées du cancer pulmonaire: tests moléculaires à partir d’échantillons cytologiques. In: Revue médicale suisse, 2011, vol. 7, n° 303, p. 1486–1490.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation11/06/2012 1:23:00 PM
First validation11/06/2012 1:23:00 PM
Update time03/14/2023 7:57:20 PM
Status update03/14/2023 7:57:19 PM
Last indexation01/16/2024 12:56:22 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack